drugset
drugset / Trial / NCT04733651

Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19

NCT04733651 ↗

Phase 2 Unknown 250 enrolled Nepal Health Research Council
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the clinical efficacy of Isoquercetin in preventing disease progression and symptoms improvement in mild-to-moderate hospitalised COVID-19 patients.

Timeline

Start
2021-02-20
Primary completion
2021-05-20
Completion
2021-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Isoquercetin Small molecule 1000 mg —

Indications

COVID-19